205 related articles for article (PubMed ID: 38009626)
1. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
[TBL] [Abstract][Full Text] [Related]
2. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
3. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
Stanczuk GA; Baxter GJ; Currie H; Forson W; Lawrence JR; Cuschieri K; Wilson A; Patterson L; Govan L; Black J; Palmer T; Arbyn M
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1629-1635. PubMed ID: 28887297
[No Abstract] [Full Text] [Related]
4. Accuracy of different triage strategies for human papillomavirus positivity in an Italian screening population.
Gustinucci D; Benevolo M; Cesarini E; Mancuso P; Passamonti B; Giaimo MD; Corvetti R; Nofrini V; Bulletti S; Malaspina M; Tintori B; Giorgi Rossi P;
Int J Cancer; 2022 Mar; 150(6):952-960. PubMed ID: 34706093
[TBL] [Abstract][Full Text] [Related]
5. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
6. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
[TBL] [Abstract][Full Text] [Related]
7. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
8. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
9. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
10. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
11. Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
Rezhake R; Chen F; Hu SY; Zhao XL; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
Int J Cancer; 2020 Oct; 147(8):2053-2064. PubMed ID: 32249409
[TBL] [Abstract][Full Text] [Related]
12. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.
Ebisch RM; van der Horst J; Hermsen M; Rijstenberg LL; Vedder JE; Bulten J; Bosgraaf RP; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Massuger LF; Melchers WJ; Bekkers RL; Siebers AG
Mod Pathol; 2017 Jul; 30(7):1021-1031. PubMed ID: 28304400
[TBL] [Abstract][Full Text] [Related]
14. p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.
Luttmer R; Dijkstra MG; Snijders PJ; Berkhof J; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; van Baal WM; Graziosi PG; Quint WG; Spruijt JW; van Dijken DK; Heideman DA; Meijer CJ
Mod Pathol; 2016 Aug; 29(8):870-8. PubMed ID: 27150161
[TBL] [Abstract][Full Text] [Related]
15. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
16. Clinical Performance of Triage Strategies for Hr-HPV-Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping.
Stanczuk G; Currie H; Forson W; Baxter G; Lawrence J; Wilson A; Palmer T; Arbyn M; Cuschieri K
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1492-1498. PubMed ID: 35511738
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial.
Wright TC; Stoler MH; Ranger-Moore J; Fang Q; Volkir P; Safaeian M; Ridder R
Int J Cancer; 2022 Feb; 150(3):461-471. PubMed ID: 34536311
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of p16/Ki-67 dual-stain as triage test for high-risk HPV-positive women: A hospital-based cross-sectional study.
Chen X; Chen C; Liu L; Dai W; Zhang J; Han C; Zhou S
Cancer Cytopathol; 2022 Dec; 130(12):955-963. PubMed ID: 35852302
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology.
Peeters E; Wentzensen N; Bergeron C; Arbyn M
Cancer Cytopathol; 2019 Mar; 127(3):169-180. PubMed ID: 30811902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
